Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response

Documenti analoghi

• Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
  di: Milojkovic, Dragana, et al.
  Pubblicazione: (2012)
• Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
  di: Marin, David, et al.
  Pubblicazione: (2010)
• Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation
  di: Milojkovic, Dragana, et al.
  Pubblicazione: (2012)
• Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
  di: Ibrahim, Amr R., et al.
  Pubblicazione: (2011)
• European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
  di: Marin, David, et al.
  Pubblicazione: (2008)